Previous Article | Next Article 
Journal of Virology, February 2005, p. 1480-1486, Vol. 79, No. 3
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.3.1480-1486.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes
Yanjie Yi,
Farida Shaheen, and
Ronald G. Collman*
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Received 5 May 2004/
Accepted 3 September 2004
Coreceptor specificity of human immunodeficiency virus type 1 (HIV-1) strains is generally defined in vitro in cell lines expressing CCR5 or CXCR4, but lymphocytes and macrophages are the principal targets in vivo. CCR5-using (R5) variants dominate early in infection, but strains that use CXCR4 emerge later in a substantial minority of subjects. Many or most CXCR4-using variants can use both CXCR4 and CCR5 (R5X4), but the pathways that are actually used to cause infection in primary cells and in vivo are unknown. We examined several R5X4 prototype and primary isolates and found that they all were largely or completely restricted to CXCR4-mediated entry in primary lymphocytes, even though lymphocytes are permissive for CCR5-mediated entry by R5 strains. In contrast, in primary macrophages R5X4 isolates used both CCR5 and CXCR4. The R5X4 strains were also more sensitive than R5 strains to CCR5 blocking, suggesting that interactions between the R5X4 strains and CCR5 are less efficient. These results indicate that coreceptor phenotyping in transformed cells does not necessarily predict utilization in primary cells, that variability exists among HIV-1 isolates in the ability to use CCR5 expressed on lymphocytes, and that many or most strains characterized as R5X4 are functionally X4 in primary lymphocytes. Less efficient interactions between R5X4 strains and CCR5 may be responsible for the inability to use CCR5 on lymphocytes, which express relatively low CCR5 levels. Since isolates that acquire CXCR4 utilization retain the capacity to use CCR5 on macrophages despite their inability to use it on lymphocytes, these results also raise the possibility that a CCR5-mediated macrophage reservoir is required for sustained infection in vivo.
* University of Pennsylvania School of Medicine, 36th & Hamilton Walk, 522 Johnson Pavilion, Philadelphia, PA 19104-6060. Phone: (215) 898-0913. Fax: (215) 573-4446. E-mail: collmanr{at}mail.med.upenn.edu.
Journal of Virology, February 2005, p. 1480-1486, Vol. 79, No. 3
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.3.1480-1486.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Veazey, R. S., Ketas, T. A., Klasse, P. J., Davison, D. K., Singletary, M., Green, L. C., Greenberg, M. L., Moore, J. P.
(2008). Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc. Natl. Acad. Sci. USA
105: 10531-10536
[Abstract]
[Full Text]
-
Tasca, S., Ho, S.-H., Cheng-Mayer, C.
(2008). R5X4 Viruses Are Evolutionary, Functional, and Antigenic Intermediates in the Pathway of a Simian-Human Immunodeficiency Virus Coreceptor Switch. J. Virol.
82: 7089-7099
[Abstract]
[Full Text]
-
Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J. D., Whitcomb, J. M., Parkin, N., Petropoulos, C. J.
(2008). Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein. J. Virol.
82: 5584-5593
[Abstract]
[Full Text]
-
Moncunill, G., Armand-Ugon, M., Clotet-Codina, I., Pauls, E., Ballana, E., Llano, A., Romagnoli, B., Vrijbloed, J. W., Gombert, F. O., Clotet, B., De Marco, S., Este, J. A.
(2008). Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026. Mol. Pharmacol.
73: 1264-1273
[Abstract]
[Full Text]
-
Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W.
(2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol.
81: 3240-3250
[Abstract]
[Full Text]
-
Goodenow, M. M., Collman, R. G.
(2006). HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J. Leukoc. Biol.
80: 965-972
[Abstract]
[Full Text]
-
Tomkowicz, B., Lee, C., Ravyn, V., Cheung, R., Ptasznik, A., Collman, R. G.
(2006). The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages. Blood
108: 1145-1150
[Abstract]
[Full Text]
-
Ancuta, P., Autissier, P., Wurcel, A., Zaman, T., Stone, D., Gabuzda, D.
(2006). CD16+ Monocyte-Derived Macrophages Activate Resting T Cells for HIV Infection by Producing CCR3 and CCR4 Ligands. J. Immunol.
176: 5760-5771
[Abstract]
[Full Text]
-
Jensen, M. A., Coetzer, M., van 't Wout, A. B., Morris, L., Mullins, J. I.
(2006). A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope v3 sequences.. J. Virol.
80: 4698-4704
[Abstract]
[Full Text]
-
Gray, L., Churchill, M. J., Keane, N., Sterjovski, J., Ellett, A. M., Purcell, D. F. J., Poumbourios, P., Kol, C., Wang, B., Saksena, N. K., Wesselingh, S. L., Price, P., French, M., Gabuzda, D., Gorry, P. R.
(2006). Genetic and Functional Analysis of R5X4 Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Derived from Two Individuals Homozygous for the CCR5{Delta}32 Allele.. J. Virol.
80: 3684-3691
[Abstract]
[Full Text]
-
Ghaffari, G., Tuttle, D. L., Briggs, D., Burkhardt, B. R., Bhatt, D., Andiman, W. A., Sleasman, J. W., Goodenow, M. M.
(2005). Complex Determinants in Human Immunodeficiency Virus Type 1 Envelope gp120 Mediate CXCR4-Dependent Infection of Macrophages. J. Virol.
79: 13250-13261
[Abstract]
[Full Text]
-
Lee, C., Tomkowicz, B., Freedman, B. D., Collman, R. G.
(2005). HIV-1 gp120-induced TNF-{alpha} production by primary human macrophages is mediated by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein (MAP) kinase pathways. J. Leukoc. Biol.
78: 1016-1023
[Abstract]
[Full Text]
-
Volberding, P. A.
(2005). The New York Case: Lessons Being Learned. ANN INTERN MED
142: 866-868
[Full Text]
Copyright © 2005 by the American Society for Microbiology. All rights reserved.